AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30184543 — intervention group
Group type: COMPARATOR
Intervention: Weekly cetuximab (250 mg/m2)
Number of subjects: 36
Study 26917072 — intervention group
Group type: COMPARATOR
Intervention: Contact Lens (CL)
Number of subjects: 112
Study 26917072 — intervention group
Group type: COMPARATOR
Intervention: Intraocular Lens (IOL)
Number of subjects: 112
Study 26917072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery before 49 days of age
Number of subjects: 112
Study 26917072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery after 49 days of age
Number of subjects: 112
Study 26917072 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotropia or microtropia (<10(Δ))
Number of subjects: 112
Study 26917072 — intervention group
Group type: EXPERIMENTAL
Intervention: Strabismus (≥10(Δ))
Number of subjects: 112
Study 26917072 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotropia
Number of subjects: 112
Study 26917072 — intervention group
Group type: EXPERIMENTAL
Intervention: Strabismus
Number of subjects: 112
Study 22809163 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced patient participation (EPP)
Number of subjects: 210
Study 22809163 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment protocol (TP)
Number of subjects: 210
Study 22276821 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m² on day 1)
Number of subjects: 1206
Study 22276821 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m² on day 1) + Capecitabine (825 mg/m² twice a day on days 1 to 14)
Number of subjects: 1206
Study 22276821 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m² on day 1) + Gemcitabine (1000 mg/m² on days 1 and 8)
Number of subjects: 1206
Study 22276821 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg for the first six cycles of chemotherapy)
Number of subjects: 1206
Study 22276821 — intervention group
Group type: COMPARATOR
Intervention: No Bevacizumab
Number of subjects: 1206
Study 20858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 5745
Study 20858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 5745
Study 20858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 5745
Study 20858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Killip class (class 3 or 4 versus 1 or 2)
Number of subjects: 5745
Study 20858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate (>70 beats per minute)
Number of subjects: 5745
Study 20858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine (>90 μmol/L)
Number of subjects: 5745
Study 20858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of ST‐segment deviations
Number of subjects: 5745
Study 20858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior STEMI location
Number of subjects: 5745
Study 20858863 — intervention group
Group type: EXPERIMENTAL
Intervention: C-index
Number of subjects: 5745
Study 17974528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 15
Study 17974528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15848695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin, sirolimus, reduced-dose cyclosporine, and corticosteroids
Number of subjects: 36
Study 15848695 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-monitoring study
Number of subjects: 36
Study 12088164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone, 80-160 mg/day (N = 148)
Number of subjects: 301
Study 12088164 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol, 5-15 mg/day (N = 153)
Number of subjects: 301
Study 12088164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 301
Study 12088164 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 301
Study 12088164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone and Haloperidol
Number of subjects: 301
Study 10206381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (moderate and heavy smokers)
Number of subjects: 1592
Study 10206381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1592
Study 7607914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative facial nerve monitoring using two different two-channel electromyography units
Number of subjects: 35
Study 7607914 — intervention group
Group type: COMPARATOR
Intervention: Control group (24 patients without monitoring)
Number of subjects: 35
Study 2221488 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazolast, 400 mg bid orally
Number of subjects: 23
Study 2221488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 74533 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated dietary fibre from bran (20 g/day)
Number of subjects: 19
Study 74533 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated dietary fibre from cabbage (20 g/day)
Number of subjects: 19
Study 74533 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated dietary fibre from carrot (20 g/day)
Number of subjects: 19
Study 74533 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated dietary fibre from apple (20 g/day)
Number of subjects: 19
Study 74533 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated dietary fibre from guar gum (20 g/day)
Number of subjects: 19
Study 31887280 — intervention group
Group type: EXPERIMENTAL
Intervention: Grid pattern
Number of subjects: 661
Study 31887280 — intervention group
Group type: EXPERIMENTAL
Intervention: Sextant pattern
Number of subjects: 661
Study 31887280 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrant pattern
Number of subjects: 661
Study 31887280 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 patterns
Number of subjects: 661
Study 30457436 — intervention group
Group type: EXPERIMENTAL
Intervention: HDC vaccine (HDCV)
Number of subjects: 100
Study 30457436 — intervention group
Group type: COMPARATOR
Intervention: Hamster kidney cell vaccine
Number of subjects: 100
Study 28482991 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm showers (40 °C to 43 °C for approximately 20 minutes)
Number of subjects: 358
Study 28482991 — intervention group
Group type: COMPARATOR
Intervention: No warm showers (control group)
Number of subjects: 358
Study 25823791 — intervention group
Group type: EXPERIMENTAL
Intervention: T-pouch ileal orthotopic neobladder
Number of subjects: 484
Study 25823791 — intervention group
Group type: COMPARATOR
Intervention: Studer ileal orthotopic neobladder
Number of subjects: 484
Study 23651537 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care Triple P (n = 34)
Number of subjects: 67
Study 23651537 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 33)
Number of subjects: 67
Study 23651537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 67
Study 23651537 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary measurements
Number of subjects: 67
Study 21338892 — intervention group
Group type: EXPERIMENTAL
Intervention: Random laboratory drug testing program (PDT)
Number of subjects: 114
Study 19149760 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study 19149760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0
Study 19149760 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 19149760 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy or EGFR inhibitors
Number of subjects: 0
Study 19149760 — intervention group
Group type: EXPERIMENTAL
Intervention: New EGFR inhibitors
Number of subjects: 0
Study 17418721 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser (10 seconds)
Number of subjects: 23
Study 17418721 — intervention group
Group type: COMPARATOR
Intervention: Conventional curing light (40 seconds)
Number of subjects: 23
Study 17418721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 23
Study 15202617 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (specifics not provided)
Number of subjects: 0
Study 15202617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 11229673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of HSV1716 (10^3 plaque-forming units)
Number of subjects: 5
Study 9745056 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 40
Study 9745056 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein mesh repair
Number of subjects: 40
Study 8156069 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive SLR with opposite hip extended
Number of subjects: 22
Study 8156069 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SLR with opposite hip extended
Number of subjects: 22
Study 8156069 — intervention group
Group type: COMPARATOR
Intervention: Trial 1
Number of subjects: 22
Study 8156069 — intervention group
Group type: COMPARATOR
Intervention: Trial 2
Number of subjects: 22
Study 3340661 — intervention group
Group type: EXPERIMENTAL
Intervention: He‐Ne laser
Number of subjects: 40
Study 3340661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29617081 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar TURBT (M‐TURBT)
Number of subjects: 90
Study 29617081 — intervention group
Group type: COMPARATOR
Intervention: Bipolar TURBT (B‐TURBT)
Number of subjects: 90
Study 26335185 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group 1 (oligomenorrhea/anovulation and hyperandrogenemia/hyperandrogenism)
Number of subjects: 89
Study 26335185 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group 2 (anovulation and polycystic ovaries)
Number of subjects: 89
Study 26335185 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group 3 (hyperandrogenemia and polycystic ovaries)
Number of subjects: 89
Study 26335185 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group 4 (anovulation, hyperandrogenemia and polycystic ovaries)
Number of subjects: 89
Study 26335185 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and weight-matched healthy controls)
Number of subjects: 89
Study 26335185 — intervention group
Group type: EXPERIMENTAL
Intervention: All PCOS groups
Number of subjects: 89
Study 25638740 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 1.2mcg/kg/hour (high dose)
Number of subjects: 24
Study 25638740 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.4mcg/kg/hour (low dose)
Number of subjects: 24
Study 25638740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23589673 — intervention group
Group type: EXPERIMENTAL
Intervention: vinblastine + prednisone + methotrexate (Arm B)
Number of subjects: 400
Study 23589673 — intervention group
Group type: COMPARATOR
Intervention: vinblastine + prednisone (Arm A)
Number of subjects: 400
Study 23589673 — intervention group
Group type: COMPARATOR
Intervention: vinblastine + prednisone (Arm C, 6 months)
Number of subjects: 400
Study 23589673 — intervention group
Group type: EXPERIMENTAL
Intervention: vinblastine + prednisone (Arm D, 12 months)
Number of subjects: 400
Study 23589673 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (LCH-I, 6 months)
Number of subjects: 400
Study 23589673 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (LCH-II, 6 months)
Number of subjects: 400
Study 21180239 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (maximal symptom limited exercise stress testing on cycloergometer)
Number of subjects: 79
Study 19138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (smokers with oral tissue methylation)
Number of subjects: 127
Study 19138934 — intervention group
Group type: COMPARATOR
Intervention: Control group (smokers without oral tissue methylation)
Number of subjects: 127
Study 19138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline methylation for p16 in bronchial tissue
Number of subjects: 127
Study 19138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline methylation for FHIT in bronchial tissue
Number of subjects: 127
Study 19138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline methylation for both p16 and FHIT in bronchial tissue
Number of subjects: 127
Study 19138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline methylation for p16 in oral tissue
Number of subjects: 127
Study 19138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline methylation for FHIT in oral tissue
Number of subjects: 127
Study 19138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline methylation for both p16 and FHIT in oral tissue
Number of subjects: 127
Study 19138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of methylation patterns between oral and bronchial tissues
Number of subjects: 127
Study 19138934 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months after intervention
Number of subjects: 127
Study 16816304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 336
Study 16816304 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 336
Study 12799402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/d)
Number of subjects: 1809
Study 12799402 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (650 mg/d)
Number of subjects: 1809
Study 11795342 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day) for up to 8 years
Number of subjects: 0
Study 11795342 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 0
Study 9175685 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical artery pulsatility index
Number of subjects: 44
Study 9175685 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical venous flow velocity
Number of subjects: 44
Study 9175685 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal aortic volume flow
Number of subjects: 44
Study 9175685 — intervention group
Group type: COMPARATOR
Intervention: Oligohydramnios
Number of subjects: 44
Study 9175685 — intervention group
Group type: COMPARATOR
Intervention: Birth asphyxia
Number of subjects: 44
Study 9175685 — intervention group
Group type: COMPARATOR
Intervention: Uterine flow
Number of subjects: 44
Study 1415419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and bed rest
Number of subjects: 200
Study 1415419 — intervention group
Group type: COMPARATOR
Intervention: Bed rest alone
Number of subjects: 200
Study 3002135 — intervention group
Group type: EXPERIMENTAL
Intervention: doxorubicin‐cyclophosphamide (DC)
Number of subjects: 102
Study 3002135 — intervention group
Group type: COMPARATOR
Intervention: cyclophosphamide‐methotrexate‐5‐fluorouracil‐vincristine‐prednisone (CMFVP)
Number of subjects: 102
Study 31917424 — intervention group
Group type: EXPERIMENTAL
Intervention: Low recurrence score (n=121)
Number of subjects: 316
Study 31917424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate or high recurrence score (n=195)
Number of subjects: 316
Study 31917424 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy without radiotherapy, low recurrence score (n=unknown)
Number of subjects: 316
Study 31917424 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy without radiotherapy, intermediate or high recurrence score (n=unknown)
Number of subjects: 316
Study 31917424 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset analysis, low recurrence score (n=unknown)
Number of subjects: 316
Study 31917424 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset analysis, intermediate or high recurrence score (n=unknown)
Number of subjects: 316
Study 31740862 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.4 MAC with propofol 1mg/kg
Number of subjects: 50
Study 31740862 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane at 1.2 MAC alone
Number of subjects: 50
Study 28694471 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate
Number of subjects: 4
Study 28694471 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% doxycycline solution
Number of subjects: 4
Study 28694471 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Proanthocyanidin (PR)
Number of subjects: 4
Study 28694471 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 4
Study 25867446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy guided self-help (CBTgsh)
Number of subjects: 205
Study 25867446 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 205
Study 25867446 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (BWL)
Number of subjects: 205
Study 25867446 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 205
Study 25867446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy guided self-help (CBTgsh) and Interpersonal psychotherapy (IPT)
Number of subjects: 205
Study 23657091 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile whole body MRI measurements at intervals of 800 km during the ultramarathon
Number of subjects: 22
Study 23657091 — intervention group
Group type: COMPARATOR
Intervention: Comparison of body composition between finishers and non-finishers
Number of subjects: 22
Study 23657091 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of visceral adipose tissue (VAT) with prerace training volume and intensity
Number of subjects: 22
Study 23657091 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of body composition changes and performance relationship
Number of subjects: 22
Study 20196109 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT‐AF (appetite focused dialectical behavior therapy)
Number of subjects: 32
Study 20196109 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 32
Study 19708562 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electrotherapy using a TRANSAIR‐02 apparatus (combined with traditional treatment)
Number of subjects: 100
Study 18044688 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 1186
Study 18044688 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg bid
Number of subjects: 1186
Study 14571451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel treatment (EF group)
Number of subjects: 98
Study 14571451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel treatment followed by argon laser irradiation (EFL group)
Number of subjects: 98
Study 14571451 — intervention group
Group type: COMPARATOR
Intervention: No treatment (E group)
Number of subjects: 98
Study 10594469 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg once daily
Number of subjects: 100
Study 10594469 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin standard (1 mg day-1 titrated to higher dose)
Number of subjects: 100
Study 10594469 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS with high-fat meal
Number of subjects: 100
Study 10594469 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg and 8 mg
Number of subjects: 100
Study 10594469 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS once daily for 7 days
Number of subjects: 100
Study 10594469 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 100
Study 8918276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily)
Number of subjects: 6595
Study 8918276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595
Study 1746667 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 450
Study 1746667 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 450
Study 6762670 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of the cervical spine with an amnesic dose of diazepam
Number of subjects: 21
Study 6762670 — intervention group
Group type: COMPARATOR
Intervention: Control group received diazepam but no manipulation
Number of subjects: 21
Study 6421359 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (10 micrograms) given at 0, 1, and 2 months of age
Number of subjects: 20
Study 6421359 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (10 micrograms) given at 3, 4, and 5 months of age
Number of subjects: 20
Study 30348353 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult spinal deformity surgery
Number of subjects: 153
Study 27276421 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) 33 mg kg(‐1) single oral dose
Number of subjects: 32
Study 27276421 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 3‐O‐glucuronide (DFP‐G)
Number of subjects: 32
Study 27276421 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety monitoring of DFP
Number of subjects: 32
Study 24134074 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% dextrose (D25)
Number of subjects: 150
Study 24134074 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose (D10)
Number of subjects: 150
Study 24134074 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 150
Study 23383461 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (true acupuncture needles), treated once every other day for 12 sessions
Number of subjects: 118
Study 23383461 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (true acupuncture needles)
Number of subjects: 118
Study 23383461 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (placebo acupuncture needles)
Number of subjects: 118
Study 20655809 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% capsaicin patch) for 30 minutes
Number of subjects: 299
Study 20655809 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% capsaicin patch) for 60 minutes
Number of subjects: 299
Study 20655809 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% capsaicin patch) for 90 minutes
Number of subjects: 299
Study 20655809 — intervention group
Group type: COMPARATOR
Intervention: Pooled control group (0.04% capsaicin patch)
Number of subjects: 299
Study 20655809 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (30 minutes)
Number of subjects: 299